Zevra Therapeutics, Inc. (ZVRA)
Zevra Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Zevra Therapeutics, Inc. (ZVRA) is a Biotechnology company based in US with a market capitalization of $736M. Revenue grew 350.9% year-over-year and free cash flow was negative at -$2.4M. This page tracks ZVRA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 59 employees · IPO Apr 16, 2015
Valuation
Valuation & price
$11.01as of May 17, 2026· -25.4% vs 52w high
7.6
P/E ratio
Latest-FY diluted EPS
4.76
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$736M
Market cap
350.9%
Revenue growth (YoY)
84.5%
Gross margin
-$2.4M
Free cash flow (USD)
-$127.8M
Net debt
Net cash position
19.6%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Zevra Therapeutics, Inc.'s market cap?
Zevra Therapeutics, Inc. (ZVRA) has a market capitalization of $736M.
What is ZVRA's P/E ratio?
ZVRA trades at a price-to-earnings ratio of 7.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is ZVRA's price-to-book (P/B) ratio?
ZVRA trades at 4.76 times book value per share.
Are insiders buying ZVRA stock?
SEC Form 4 filings show no open-market insider buys at Zevra Therapeutics, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.